These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22251566)

  • 1. Cannabinoid receptor signaling and modulation of monoamines: implications for psychiatric and neurological disorders.
    Van Bockstaele EJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):1-3. PubMed ID: 22251566
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders.
    de Oliveira RW; Oliveira CL; Guimarães FS; Campos AC
    Acta Neuropsychiatr; 2019 Feb; 31(1):1-16. PubMed ID: 29764526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid receptors and their relationships with neuropsychiatric disorders.
    Gambi F; De Berardis D; Sepede G; Quartesan R; Calcagni E; Salerno RM; Conti CM; Ferro FM
    Int J Immunopathol Pharmacol; 2005; 18(1):15-9. PubMed ID: 15698507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.
    Haspula D; Clark MA
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33080916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects.
    Davis BA
    J Chromatogr; 1989 Apr; 466():89-218. PubMed ID: 2663901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the endocannabinoid system in neurological disorders.
    Zou M; Li D; Li L; Wu L; Sun C
    Int J Dev Neurosci; 2019 Aug; 76():95-102. PubMed ID: 30858029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases.
    van Neerven S; Kampmann E; Mey J
    Prog Neurobiol; 2008 Aug; 85(4):433-51. PubMed ID: 18554773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders.
    Esteban S; García-Sevilla JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):78-87. PubMed ID: 22133541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric Disorders and Cannabinoid Receptors.
    Joshi N; Onaivi ES
    Adv Exp Med Biol; 2021; 1264():131-153. PubMed ID: 33332008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of signaling of cannabinoids receptors: paving a way for rational drug design in controling mutiple neurological and immune diseases.
    Huang S; Xiao P; Sun J
    Signal Transduct Target Ther; 2020 Jul; 5(1):127. PubMed ID: 32694501
    [No Abstract]   [Full Text] [Related]  

  • 11. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.
    van der Stelt M; Di Marzo V
    Eur J Pharmacol; 2003 Nov; 480(1-3):133-50. PubMed ID: 14623357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk of metabolic factors and neurogenic signaling in adult neurogenesis: Implication of metabolic regulation for mental and neurological diseases.
    Gao C; Wang Q; Chung SK; Shen J
    Neurochem Int; 2017 Jun; 106():24-36. PubMed ID: 28188802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.
    Turner CA; Eren-Koçak E; Inui EG; Watson SJ; Akil H
    Semin Cell Dev Biol; 2016 May; 53():136-43. PubMed ID: 26454097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):68-77. PubMed ID: 22234284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.
    Wyrofsky R; McGonigle P; Van Bockstaele EJ
    Expert Opin Drug Discov; 2015 Jan; 10(1):17-36. PubMed ID: 25488672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A renaissance in trace amines inspired by a novel GPCR family.
    Lindemann L; Hoener MC
    Trends Pharmacol Sci; 2005 May; 26(5):274-81. PubMed ID: 15860375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders.
    Ramirez AD; Smith SM
    Cent Nerv Syst Agents Med Chem; 2014; 14(2):72-82. PubMed ID: 25540976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdisciplinary chemical approaches for neuropathology.
    Ramsay RR; Di Giovanni G
    CNS Neurosci Ther; 2014 Jul; 20(7):571-3. PubMed ID: 24935786
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychopharmacology.
    Cameron OG
    Psychosom Med; 1999; 61(5):585-90. PubMed ID: 10511009
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurocognitive deficits in major depression and a new theory of ADHD: a model of impaired antagonism of cholinergic-mediated prepotent behaviours in monoamine depleted individuals.
    Vakalopoulos C
    Med Hypotheses; 2007; 68(1):210-21. PubMed ID: 16997497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.